Canine Babesiosis - Cerebral Form: Diagnosis, Differentials & Treatment Plan

Case Summary & Key Clinical Interpretation

• Cycling/paddling movement in lateral recumbency (opisthotonus posture with head towards sky = opisthotonus/head dorsiflexion)
• History of dog bite/trauma from a German Shepherd (direct inoculation route)
• Vaccinated but NOT dewormed
• Blood smear: Babesia gibsoni confirmed
• No haemoprotozoa on initial smear (B. gibsoni parasitemia can be very low and missed on smear - this finding does NOT rule out disease; PCR is gold standard)

PRIMARY DIAGNOSIS

Cerebral Babesiosis (Complicated Canine Babesiosis) - Babesia gibsoni

1. Cerebral hypoxia - parasitized red blood cells have reduced oxygen-carrying capacity; microvascular sequestration of parasitized RBCs occurs in brain capillaries
2. Hypoglycemia - B. gibsoni-infected dogs frequently develop profound hypoglycemia which directly causes seizure-like activity and opisthotonus
3. Cerebrovascular compromise - cytoadherence and rosetting of infected erythrocytes causes microcirculatory obstruction in cerebral vessels
4. Systemic inflammatory response (SIRS) - massive cytokine release causes cerebral edema and dysfunction
5. Disseminated Intravascular Coagulation (DIC) - secondary coagulopathy leads to petechial hemorrhages including cerebral microhemorrhages

DIFFERENTIAL DIAGNOSES

Neurological/Systemic Differentials (in order of priority):

TREATMENT PLAN

EMERGENCY STABILIZATION (First Priority)

1. IV Access immediately - place IV catheter
2. Blood glucose - check STAT; cerebral babesiosis causes profound hypoglycemia
   • If hypoglycemic: 50% dextrose IV bolus (0.5-1 mL/kg diluted 1:4 with saline), then maintain on 2.5-5% dextrose in fluids
3. IV fluid therapy - Lactated Ringer's or 0.9% NaCl; correct dehydration, maintain perfusion
4. Seizure control - if active seizures/cycling movement:
   • Diazepam 0.5 mg/kg IV slowly OR Midazolam 0.2-0.3 mg/kg IV/IM
   • Phenobarbital 2-5 mg/kg IV if refractory
5. Oxygen therapy - cerebral hypoxia is a key mechanism; supplement oxygen
6. Blood transfusion - indicated if PCV < 15-20%; CRUCIAL in puppies
   • Whole blood or packed RBCs (10-20 mL/kg over 4-6 hours)

SPECIFIC ANTI-BABESIA TREATMENT

FIRST-LINE PROTOCOL (Evidence-Based, 2022-2026):

• Give atovaquone WITH a fatty meal (critical for absorption)
• Karasova 2022 showed NO relapses at 2-year follow-up with this triple combination
• PCR monitoring recommended at Day 60; retreat if still positive

SECOND-LINE / ALTERNATIVE (if atovaquone unavailable or cost-prohibitive):

• 5-7.5 mg/kg IM, repeated 2-3 times at 2-week intervals for B. gibsoni
• NOT curative - reduces parasitemia but does not clear infection
• Pre-treat with atropine (0.04 mg/kg SC) to prevent cholinergic side effects
• Avoid if neurological signs are severe (can worsen neurological signs at high doses)

SUPPORTIVE TREATMENT

DEWORMING (Important Given History)

• Fenbendazole 50 mg/kg PO q24h x 3 days (broad-spectrum, safe in puppies)
• Rule out Neospora caninum if neurological signs persist post-babesia treatment (serology + PCR; Neospora causes ascending hind limb paralysis/rigidity in puppies)

DIAGNOSTIC WORKUP TO COMPLETE

1. PCR for B. gibsoni - gold standard; blood smear misses low parasitemia; confirms species and baseline load
2. CBC - PCV, hemoglobin, platelet count, WBC differential
3. Blood glucose - STAT (cerebral hypoxia/hypoglycemia is the mechanism of cycling)
4. Serum biochemistry - BUN, creatinine, ALT, AST, bilirubin, albumin
5. Urinalysis - hemoglobinuria, bilirubinuria, proteinuria
6. Coagulation profile - PT/aPTT (rule out DIC)
7. Blood pressure - hypotension is common
8. Thoracic radiographs - rule out pulmonary edema/ARDS
9. Abdominal ultrasound - splenomegaly, hepatomegaly, renal changes
10. PCR panel for co-infections - Ehrlichia canis, Anaplasma platys, Hepatozoon canis (especially if not responding to treatment)

PROGNOSIS

• Cerebral babesiosis carries a guarded to poor prognosis, especially in young puppies
• Mortality increases with: hypoglycemia, DIC, multi-organ dysfunction, delay in treatment
• Dogs that survive the acute phase can become chronic carriers - B. gibsoni is rarely completely eliminated without the AAA triple combination
• PCR monitoring at 60, 180, 360 days is essential to confirm clearance

KEY REFERENCES (Peer-Reviewed)

• Karasova et al. - Malarone + AZM + Artesunate efficacy (Animals, 2022) - PMID 35327106
• Pati et al. - AAA vs DCM comparative efficacy (Vet Parasitol, 2026) - PMID 42289158
• Almendros et al. - Metronidazole + Clindamycin + Doxycycline alternative (J Vet Med Sci, 2020) - PMID 32759546
• Karasova et al. - Etiology, Incidence, Pathogenesis, Diagnostics & Treatment of B. gibsoni (MDPI Animals, 2022) - comprehensive review
• Gunawardhana et al. - CYTb mutations and drug resistance (Vet Parasitol, 2025) - PMID 41354536 - critical for monitoring resistance with atovaquone

Drug resistance note: The 2025 Korean study (PMID 41354536) identified CYTb gene mutations in B. gibsoni correlating with atovaquone resistance. If the AAA regimen fails, resistance testing via pyrosequencing of the cytochrome b gene is recommended before retreating.